Summit Securities Group’s Biogen BIIB Stock Holding History

Summit Securities Group’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,000	Closed	-$204K	–	937
2022 Q2	$204K	Buy	+1,000	New	+$204K	0.03%	297
2022 Q1	–	Sell	-200	Closed	-$48K	–	1105
2021 Q4	$48K	Buy	+200	New	+$51.4K	﹤0.01%	730
2020 Q3	–	Sell	-30	Closed	-$803K	–	370
2020 Q2	$803K	Buy	+30	New	+$9.02K	0.1%	172
2020 Q1	–	Sell	-118	Closed	-$3.5M	–	308
2019 Q4	$3.5M	Buy	+118	New	+$32.7K	0.26%	86
2019 Q2	–	Sell	-40	Closed	-$946K	–	327
2019 Q1	$946K	Buy	+40	New	+$12.6K	0.17%	83
2018 Q3	–	Sell	-40	Closed	-$1.16M	–	200
2018 Q2	$1.16M	Hold	40	–	–	0.17%	77
2018 Q1	$1.09M	Buy	+40	New	+$12.4K	0.27%	55

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Summit Securities Group's BIIB Position: Q1 2026 in Review

Summit Securities Group reduced its Biogen (BIIB) stake by 89% in Q1 2026, selling an estimated $35.9K and leaving 24 shares worth $4.4K. The position accounts for ﹤0.01% of the portfolio, ranked #822.

Summit Securities Group first reported a position in BIIB in Q1 2016 and has held it in 14 quarters since. The position peaked at $1.71M in Q1 2016. 1,003 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

Summit Securities Group held 24 shares of Biogen worth $4.4K as of Q1 2026.
Summit Securities Group sold 195 Biogen shares in Q1 2026, an estimated $35.9K.
Biogen made up ﹤0.01% of Summit Securities Group's portfolio in Q1 2026, its #822 holding.
Summit Securities Group first reported a position in Biogen in Q1 2016 and has held it in 14 quarters since.
Summit Securities Group's Biogen position peaked at $1.71M in Q1 2016.
1,003 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Summit Securities Group's 13F filing for Q1 2026, filed 30 Apr 2026.